Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.50 |
| ▸ | DTYMK | P23919 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471801 | 0.91 | TYMS (0.52) | POLB | |
| SCHEMBL8417572 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL10022245 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL5664015 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22327108 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL5664002 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL8417580 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492015 | 0.90 | POLG (0.50) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492103 | 0.90 | POLG (0.50) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22189180 | 0.90 | POLG (0.53) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240344109-A1 | METHODS OF DETERMINING THE NUMBER OF COPIES OR SEQUENCE OF ONE OR MORE RNA MOLECULES | BASIC GENOMICS AB (SE) | 2024-10-17 | — | — | US | claimed |
| EP-4381093-A1 | METHODS OF DETERMINING THE NUMBER OF COPIES OR SEQUENCE OF ONE OR MORE RNA MOLECULES | Basic Genomics AB (SE) | 2024-06-12 | — | — | EP | claimed |
| CN-117813393-A | Method for determining copy number or sequence of one or more RNA molecules | 基础基因组学公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2023012065-A1 | METHODS OF DETERMINING THE NUMBER OF COPIES OR SEQUENCE OF ONE OR MORE RNA MOLECULES | BASIC GENOMICS AB (SE) | 2023-02-09 | — | — | WO | claimed |
| US-20190100784-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac SE (DE) | 2019-04-04 | — | — | US | claimed |
| EP-3423595-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac AG (DE) | 2019-01-09 | — | — | EP | claimed |
| US-20160289679-A1 | NUCLEIC ACID LIGANDS TO LL37 | BIOTEX INC (US) | 2016-10-06 | — | — | US | claimed |
| US-20150259688-A1 | NUCLEIC ACID LIGANDS TO LL37 | BIOTEX INC (US) | 2015-09-17 | — | — | US | claimed |
| US-9044495-B2 | Nucleic acid ligands to LL37 | BIOTEX, INC. (US) | 2015-06-02 | — | — | US | claimed |
| US-20120121533-A1 | NUCLEIC ACID LIGANDS TO LL37 | BIOTEX, INC. (US) | 2012-05-17 | — | — | US | claimed |
| EP-4747380-A1 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | CRISPR Therapeutics AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122070365-A | Systems and compositions comprising highly active trans-amplified replicase | 百欧恩泰欧洲股份公司 | 2026-05-19 | — | — | CN | disclosed |
| US-9044495-B2 | Nucleic acid ligands to LL37 | BIOTEX, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| WO-2015062738-A1 | MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120121533-A1 | NUCLEIC ACID LIGANDS TO LL37 | BIOTEX, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | BENNER STEVEN A | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | RNGTT, POLRMT, DNTT | POLG 89/4885POLB 28/4885P2RY2 1132/4885 |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | ADAR, RNGTT, UPF1 | POLG 3051/4885POLB 1949/4885P2RY2 1015/4885 |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | RNMT, RNGTT, NSUN3 | POLG 1112/4885POLB 733/4885P2RY2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.